Israel Medical Innovation - Israeli-South African Trade, Technology ...
Israel Medical Innovation - Israeli-South African Trade, Technology ...
Israel Medical Innovation - Israeli-South African Trade, Technology ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Israel</strong> <strong>Medical</strong> <strong>Innovation</strong>2011<br />
Motorika<br />
www.motorika.com<br />
Category:<br />
<strong>Medical</strong> and<br />
Hospital Equipment<br />
Robotics<br />
Rehabilitation<br />
Neurology and<br />
Degenerative<br />
Diseases<br />
General Health<br />
Company Status:<br />
Revenue Growth<br />
Company at a Glance<br />
Motorika is a leader in manufacturing robot-assisted solutions to meet the therapeutic needs<br />
of patients suffering from a variety of neurological conditions, including stroke, traumatic<br />
brain injury, spinal cord injury, as well as orthopedic and post-surgery dysfunction.<br />
Motorika's products include upper and lower extremities function, providing better<br />
rehabilitation results through a combination of wide variation and intense repetition.<br />
<strong>Technology</strong> and Product(s)<br />
ReoGo is the world’s most advanced robotic system for upper limb therapy, designed to<br />
facilitate three-dimensional repetitive arm movements through the use of an advanced,<br />
fully motorized robotic arm. The system is suited for a wide variety of patients in all stages<br />
of stroke recovery.<br />
ReoAmbulator is a high-end robotic gait training device that integrates Body Weight-<br />
Support Treadmill Training (BWSTT) with advanced robotics to help rehabilitate patients<br />
who experience problems with ambulation, balance, coordination, posture or stamina.<br />
Goal<br />
Objectives: Generate interest from doctors and physiotherapists<br />
Target Businesses: Hospitals, rehabilitation clinics<br />
Target Countries: Worldwide<br />
Schedule a Meeting at<br />
Return to Table of Content<br />
44
Change language